Volume is out of sight.
Wait until they get the stem cell results from their other candidate:
Candidate & Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
Cell Therapy* |
NSI-566 US Amyotropic Lateral Sclerosis | Preclinical Phase complete | Phase 1 Phase complete | Phase 2 Phase in progress | Phase 3 Phase not started |
NSI-566 US Chronic Spinal Cord Injury | Preclinical Phase complete | Phase 1 Phase in progress | Phase 2 Phase not started | Phase 3 Phase not started |
NSI-566 China Ischemic Stroke | Preclinical Phase complete | Phase 1 Phase in progress | Phase 2 Phase not started | Phase 3 Phase not started |
*Neuralstem corporate strategy is to seek partnerships/collaborations to fund the programs.